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Increased phosphorylation of collapsin
response mediator protein-2 at Thr514
correlates with β-amyloid burden and
synaptic deficits in Lewy body dementias
Huayang Xing1, Yun-An Lim1,2, Joyce R. Chong1, Jasinda H. Lee1, Dag Aarsland3,4, Clive G. Ballard5, Paul T. Francis5,
Christopher P. Chen1,2 and Mitchell K. P. Lai1,2,5*
Abstract
Collapsin response mediator protein-2 (CRMP2) regulates axonal growth cone extension, and increased CRMP2
phosphorylation may lead to axonal degeneration. Axonal and synaptic pathology is an important feature of Lewy
body dementias (LBD), but the state of CRMP2 phosphorylation (pCRMP2) as well as its correlations with markers
of neurodegeneration have not been studied in these dementias. Hence, we measured CRMP2 phosphorylation
at Thr509, Thr514 and Ser522, as well as markers of β-amyloid (Aβ), tau-phosphorylation, α-synuclein and synaptic
function in the postmortem neocortex of a longitudinally assessed cohort of LBD patients characterized by low
(Parkinson’s disease dementia, PDD) and high (dementia with Lewy bodies, DLB) burden of Alzheimer type pathology.
We found specific increases of pCRMP2 at Thr514 in DLB, but not PDD. The increased CRMP2 phosphorylation
correlated with fibrillogenic Aβ as well as with losses of markers for axon regeneration (β-III-tubulin) and synaptic
integrity (synaptophysin) in LBD. In contrast, pCRMP2 alterations did not correlate with tau-phosphorylation or
α-synuclein, and also appear unrelated to immunoreactivities of putative upstream kinases glycogen synthase
kinase 3β and cyclin-dependent kinase 5, as well as to protein phosphatase 2A. In conclusion, increased pCRMP2
may underlie the axonal pathology of DLB, and may be a novel therapeutic target. However, antecedent signaling
events as well as the nature of pCRMP2 association with Aβ and other neuropathologic markers require further study.
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Introduction
Collapsin response mediator protein-2 (CRMP2) is the
first identified member of the collapsin response medi-
ator protein (CRMP) family [1]. There are five known
isoforms, CRMP1-5, of which only CRMP2 (also known
as dihydropyrimidinase-like 2) expression remains high
in the adult brain [2, 3] and is known to promote
axonal pathfinding during neural development by medi-
ating semaphorin 3A-induced growth cone collapse [1].
Physiologically, CRMP2 is also involved in neurotrans-
mitter release, neuronal migration, as well as in axonal
transport and guidance [4–7]. CRMP2 can be phos-
phorylated at Ser522 by cyclin-dependent kinase 5
(CDK5), which in turn facilitates glycogen synthase
kinase 3β (GSK3β)-mediated phosphorylation at Thr509
and Thr514 [7–10]. CDK5 can be activated by p35 or its
calpain cleavage product, p25 [11], while GSK3β activity
is activated by phosphorylation at Tyr216 and inhibited
by phosphorylation at Ser9 [12]. Phosphorylation of
CRMP2 decreases CRMP2 binding activity to tubulin,
thereby inhibiting neurite outgrowth [10] and potentially
leading to axonal degeneration [13], whilst dephosphory-
lation of CRMP2 by protein phosphatase 2A (PP2A) en-
hances axonal growth [14]. Axonopathy and associated
synaptic dysfunction are early features of Alzheimer’s
disease (AD), currently the commonest cause of neuro-
degenerative dementia in the elderly [15]. Besides syn-
aptic deficits, the neuropathological hallmarks of AD
include aggregated β-amyloid (Aβ)-containing senile
plaques and neurofibrillary tangles consisting of hyper-
phosphorylated tau proteins. Interestingly, CRMP2
phosphorylation has been found to be increased in AD,
suggesting that CRMP2 phosphorylation is associated
with Aβ pathology, and that CRMP2 dysregulation may
be one mechanism underlying axonopathy and neurite
degeneration [16, 17]. Besides AD, Lewy body demen-
tias (LBD) constitute the second largest cause of neuro-
degenerative dementias [18] and encompass both
Parkinson’s disease with dementia (PDD) and dementia
with Lewy bodies (DLB). PDD and DLB share similar
neuropathological features, especially with respect to
presence of cortical aggregated α-synuclein-containing
Lewy bodies [19], and differentiation is mainly clinical,
based on the “one-year rule” where patients presenting
with dementia before, or within a year of, parkinsonism
are diagnosed with DLB, while dementia occurring > 1 year
after parkinsonism is considered to be PDD [20]. Im-
portantly however, PDD has relatively low burden of
Aβ plaques, while DLB has variable but generally higher
Aβ burden [21–23]. However, the status of CRMP2 in
LBD, and whether CRMP2 phosphorylation is related
to Aβ and /or α-synuclein load is at present unclear. As
there is as yet no licensed treatment for DLB, we aimed
to assess if CRMP2 phosphorylation may represent a
potential therapeutic target. Therefore, we measured
CRMP2 phosphorylation, Aβ, tau phosphorylation and
α-synuclein, together with markers of axonal and syn-
aptic deficits in the postmortem neocortex of a cohort
of longitudinally assessed PDD and DLB patients.
Results
Demographic and disease variables of the study cohort
Table 1 lists the demographic and disease variables of
the control, DLB and PDD, indicating that subjects were
well-matched in age, postmortem delay and brain pH
(mean values ranging from 6.3-6.5), with the latter used
as an indicator of tissue quality, and pH above 6.1 con-
sidered acceptable [24]. In agreement with findings of
higher AD pathological burden in DLB [23], higher
proportions of Braak stage V/VI were found in DLB
than PDD, while none of the control subjects were
staged higher than Braak III (Table 1).
CRMP2 is enriched in soluble cytosolic fractions of
postmortem human neocortex
CRMP2 is known to be abundantly localized to the
cytosol as a cytoskeletal associated protein [25], which
has previously been shown to be enriched in cytosolic
soluble fractions, along with actin [26, 27]. To further
characterize CRMP2 distribution, equal amounts of
protein from total and cytosolic fractions of brain
homogenates were immunoblotted for CRMP2. As ex-
pected, CRMP2 immunoreactivity was enriched in the
cytosolic fraction, along with β-actin (Additional file 1:
Figure S1). We therefore measured total and phosphor-
ylated CRMP2 in the cytosolic, soluble fractions for
correlations with soluble Aβ peptides from the same
fractions (see below).
Table 1 Demographic and disease variables of control and
LBD subjects
Demographics Control PDD DLB
Maximum N 19 19 20
Gender (Male/Female) 11/8 8/11 10/10
Age at Death (years) 81.8 ± 1.5 80.1 ± 1.4 81.0 ± 1.3
Postmortem Interval (hours)a 38.6 ± 5.6 31.4 ± 3.8 35.0 ± 5.8
Brain pH 6.46 ± 0.06 6.44 ± 0.06 6.37 ± 0.06
Disease variables
Braak Stageb 0 3 1 0
I/II 11 13 4
III/IV 1 3 8
V/VI 0 2 8
Data are expressed as mean ± SEM. NA not available
aPostmortem interval data was not available for one PDD patient
bFour controls were not Braak staged
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Specific increases of CRMP2 phosphorylation at Thr514
in DLB
Because previous studies on AD have reported increased
CRMP2 phosphorylation which may be related to amyloid
burden [16, 17], we were interested in studying these asso-
ciations in LBD, and compared the immunoreactivities of
cytosolic phosphorylated CRMP2 between the two clinical
subgroups known to manifest relatively high (DLB) and
low (PDD) cortical Aβ [21–23]. Interestingly, while total
CRMP2 levels were unchanged (Fig. 1a), pThr514 CRMP2
was increased in DLB (Fig. 1b). In contrast, phosphory-
lated CRMP2 at Thr509, Ser522, or triply phosphorylated
Thr509, Ser518 and Ser522 as recognized by the 3 F4 anti-
body [7] were not significantly altered in either DLB or
PDD compared to controls (Fig. 1b). pThr514 CRMP2
was similarly increased in DLB, but not PDD in the total
homogenate fractions (Additional file 2: Figure S2).
Increased pThr514 CRMP2 correlates with Aβ42 to Aβ40
ratio in DLB
The 42 amino-acid species of Aβ (Aβ42) is more fibrillo-
genic and prone to forming toxic oligomers compared to
Aβ40 [28], and is the major component of amyloid pla-
ques, a pathological hallmark of AD. The Aβ42 to Aβ40
Fig. 1 Increased CRMP2 phosphorylation at Thr514 in LBD parietal cortex. a Bar graph of total CRMP2 immunoreactivity (mean ± SEM in arbitrary
units). b Representative immunoblots (with molecular weight indicators in kDa to the left of the immunoblots) and bar graphs of pCRMP2
immunoreactivities (mean ± SEM in arbitrary units) at the indicated epitopes, with GAPDH as loading control. Available N for control (C) = 19;
PDD (P) = 19 and DLB (D) = 20. *p < 0.05; **p < 0.01, significant differences for multiple pair-wise comparisons (one-way ANOVA with Bonferroni
post-hoc tests)
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ratio (Aβ42 : Aβ40) is therefore used as an indicator of
neurotoxicity and disease severity in AD [29]. Aβ42 :
Aβ40 is also a biomarker for AD clinical assessment and
has been shown to be more consistently associated with
cognitive impairments than only Aβ42 or Aβ40 [30, 31].
Corroborating previous studies on the differences in
amyloid burden between DLB and PDD [21–23], we
found that Aβ42 : Aβ40 in BA40 was significantly in-
creased in DLB, but not PDD (Fig. 2a). The Aβ42 : Aβ40
correlated with pThr514 CRMP2 immunoreactivity in
the combined LBD (DLB + PDD) group (Fig. 2b), an ob-
servation which seemed to be driven predominantly by
DLB (Fig. 2c) and not PDD (Fig. 2d). In contrast, none of
the other pCRMP2 species measured were correlated with
Aβ42 : Aβ40 (Additional file 3: Figure S3). Additionally,
measures of tau phosphorylated at Ser396 (a marker for
neurofibrillary tangle burden [32]), α-synuclein mono-
mers, as well as the insoluble, potentially pathogenic
pSer129 α-synuclein [33] did not correlate with pThr514
CRMP2 (Additional file 4: Figure S4, Additional file 5:
Figure S5 and Additional file 6: Figure S6) or with other
pCRMP2 species (data not shown).
Increased pThr514 CRMP2 correlates with synaptic
deficits in LBD
CRMP2 phosphorylation, including pThr514, is known
to deactivate CRMP2 and affect axonal growth cone as
well as associated synaptic function and plasticity [10,
34, 35]. To study possible synaptic effects of increased
pThr514 CRMP2, we correlated pThr514 immunoreac-
tivity with markers of regenerating axon/growth cone
(β-III-tubulin [36, 37]) and synaptic integrity (synapto-
physin [38]). Both β-III-tubulin and synaptophysin were
decreased in DLB, with intermediate values in PDD
(Figs. 3a and 4a). These results indicate the presence of
synaptic deficits in LBD, especially with concomitant Aβ
burden. Interestingly, pThr514 CRMP2 negatively corre-
lated with both β-III-tubulin and synaptophysin in LBD
(Figs. 3b and 4b), although for β-III-tubulin the correla-
tions were not significant within the dementia subgroups
(Fig. 3c and d), while correlations remained significant
in DLB, but not PDD, in the case of synaptophysin
(Fig. 4c and d). Taken together, the data suggest that
increased pThr514 CRMP2 is associated with deficits in
axonal regeneration and synaptic integrity in LBD.
Alterations of CDK5 activator p25 and GSK3β in LBD
To investigate whether the increased pThr514 CRMP2
may be associated with changes in upstream kinases, we
measured total CDK5 and GSK3β as well as indicators
of activation (p25, p35, pTyr216 GSK3β) and inactiva-
tion (pSer9 GSK3β). Furthermore, given that PP2A can
dephosphorylate CRMP2 at Thr514 [14], the catalytic C-
subunit of PP2A was also assessed. Figure 5 shows that
Fig. 2 Increased pThr514 CRMP2 correlates with Aβ42 : Aβ40 in LBD parietal cortex. a Bar graph of mean (± SEM) Aβ42 to Aβ40 ratios. Scatter plots
of pThr514 CRMP2 with Aβ42 : Aβ40 in cytosolic fractions of b LBD (DLB + PDD), c DLB and d PDD parietal cortex, with insets indicating rho and
p values. Where a correlation is significant, a best-fit regression line (solid line) is added together with its 95 % prediction intervals (dotted lines).
Available N for control = 19; PDD = 19 and DLB = 20. §p < 0.05; §§p < 0.01, significant differences for multiple pair-wise comparisons (Kruskal-Wallis H
with Dunn’s post-hoc tests). *p < 0.05; **p < 0.01, significant Spearman correlations
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while CDK5 levels were unchanged in LBD, there was a
loss of p25 in DLB, while p35 showed similar trends not
reaching statistical significance. In contrast, GSK3β
levels were reduced in both PDD and DLB (Fig. 6),
together with decreases of GSK3β phosphorylation at
both Tyr216 (PDD and DLB) and Ser9 (PDD). However,
when normalized to total GSK3β, neither pTyr216
GSK3β/GSK3β nor pSer9 GSK3β/GSK3β was signifi-
cantly different between the groups (Fig. 6), indicating
the loss of total GSK3β immunoreactivity rather than
changes in activation status. Lastly, no alterations of
PP2A C-subunit was observed in LBD (Additional file 7:
Figure S7), suggesting that altered pThr514 CRMP2 may
not be related to changes in dephosphorylation activity.
Discussion
The CRMP2 member of the collapsin response mediator
protein family has well-established roles in various syn-
aptic functions, including regulation of neurotransmitter
release, axonogenesis and axon guidance [4–7]. It is
therefore not surprisingly that CRMP2 alterations have
been well characterized in AD [16, 17, 39] where synaptic
dysfunction represents a prominent pathophysiological
feature [40]. However, CRMP2 alterations have not been
studied in LBD. In this study, we showed in DLB parietal
cortex a specific increase of CRMP2 phosphorylation at
Thr514 (Fig. 1), which is known to reduce CRMP2 bind-
ing affinity to molecules involved in axonal growth and
microtubule dynamics, thereby inhibiting axonal function
and leading to axonal pathology [6, 41–44]. The increased
pThr514 CRMP2 correlated with Aβ burden (as denoted
by Aβ42 : Aβ40, see Fig. 2) as well as with reductions in
markers of axonal regeneration and synaptic integrity
(Figs. 3 and 4). Therefore, increased CRMP2 phosphoryl-
ation may be one mechanism underlying the detrimental
effects of Aβ on synapses in LBD, similar to that seen in
AD [16, 17]. There has been an ongoing debate on
whether the two clinical subtypes of LBD (PDD and DLB),
whilst distinguishable by the one-year rule and other
cognitive features [20], are in fact different disease
Fig. 3 Increased pThr514 CRMP2 correlates with β-III-tubulin loss in in LBD parietal cortex. a Bar graph of β-III-tubulin immunoreactivity
(mean ± SEM in arbitrary units) and representative immunoblots, with GAPDH as loading control. Scatter plots of pThr514 CRMP2 with β-III-tubulin
immunoreactivities in total homogenate fractions of b LBD (DLB + PDD), c DLB and d PDD parietal cortex, with insets indicating rho and p values.
Where a correlation is significant, a best-fit regression line (solid line) is added together with its 95 % prediction intervals (dotted lines). Available
N for control (C) = 19; PDD (P) = 19 and DLB (D) = 20. §§p < 0.01, significant difference for multiple pair-wise comparisons (one-way ANOVA with
Bonferroni post-hoc tests). *p < 0.05, significant Spearman correlation
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Fig. 4 Increased pThr514 CRMP2 correlates with synaptophysin loss in in LBD parietal cortex. a Bar graph of synaptophysin immunoreactivity
(mean ± SEM in arbitrary units) and representative immunoblots, with GAPDH as loading control. Scatter plots of pThr514 CRMP2 with synaptophysin
immunoreactivities in total homogenate fractions of b LBD (DLB + PDD), c DLB and d PDD parietal cortex, with insets indicating rho and p values.
Where a correlation is significant, a best-fit regression line (solid line) is added together with its 95 % prediction intervals (dotted lines). Available
N for control (C) = 19; PDD (P) = 19 and DLB (D) = 20. §p < 0.05, significant difference for multiple pair-wise comparisons (one-way ANOVA with
Bonferroni post-hoc tests). *p < 0.05, significant Spearman correlations
Fig. 5 Decreased CDK5 activator, p25 in DLB parietal cortex. a Representative immunoblots and b bar graphs of p25, p35 and total CDK5
immunoreactivities (mean ± SEM in arbitrary units), with GAPDH used as a loading control. Available N for control (C) = 19; PDD (P) = 19 and
DLB (D) = 20. **p < 0.01, significant difference for multiple pair-wise comparisons (one-way ANOVA with Bonferroni post-hoc tests)
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entities, or are different manifestations in the spectrum
of LBD [19, 45–47]. In this study, we showed both
increases in pThr514 CRMP2 (Fig. 1) and decreases in
synaptic markers (Figs. 3 and 4) to be more severe in
LBD, which is known to have relatively higher Aβ bur-
den; while PDD, which has a low Aβ burden, showed
intermediate changes not reaching statistical significance
[21–23] (also see Fig. 2a). Interestingly, PDD and DLB are
known to have similar α-synuclein loads as well as Lewy
body burden [19, 48, 49] (also see Additional file 5: Figure
S5), suggesting that at least some of the identified
neurochemical differences between PDD and DLB
could be driven by the different Aβ burden in the
subtypes. This postulate is recently supported by the
finding that low cerebrospinal fluid Aβ42 values pre-
dicted a more rapid cognitive decline in DLB [50].
The clinical implications of this postulate include the
potential efficacy of novel AD pharmacotherapeutics
in DLB, particularly those targeting Aβ-related disease
process, and the impetus to include DLB patients
alongside AD patients in trials of such therapeutics.
Furthermore, suppression of CRMP2 phosphorylation
has been found to improve learning and memory defi-
cits in an AD model [51] and ameliorate axonopathy
in a multiple sclerosis model [13], thus pointing to
CRMP2 as a therapeutic target in axonopathy-related
neurodegenerative diseases. Our study now extends
the potential pathogenicity of CRMP2 phosphoryl-
ation to the axonal pathology of DLB [52, 53].
While the current study investigated a comprehensive
range of CRMP2 neurochemical markers and neuro-
pathological correlates, there are several limitations and
questions which require follow-up investigations. First,
due to issues of tissue availability, we limited our mea-
surements to the parietal cortex (BA40). Although previ-
ous studies have shown similar involvement of plaques,
tangles and α-synuclein pathology between BA40 and
other neocortical regions like the frontal or temporal
cortex [23], it is unclear whether the findings in BA40
are representative of other areas, and follow-up mea-
surements of CRMP2 in various brain regions will be
needed. Similarly, we showed that markers of neurofib-
rillary tangles (pSer396 tau) are increased in DLB, akin
to observations in AD [54]. However, pSer396 tau changes
did not reach statistical significance due to variability (see
Additional file 4: Figure S4a), and higher N’s may be
needed to have sufficient power to study potential correla-
tions between different pCRMP2 species and tau phos-
phorylation, especially since certain pCRMP2, e.g., 3 F4
epitopes, are known to be associated with neurofibrillary
tangles [55]. With regards to α-synuclein, we found no
difference in levels of monomeric species in agreement
with previous studies [48, 49], and no correlations
between α-synuclein and pCRMP2 (Additional file 5:
Figure S5). In contrast, α-synuclein phosphorylated at
Ser129 in insoluble fractions was significantly elevated
in DLB, whilst PDD showed intermediate levels, and
may be more specific to [56], and pathogenic in [57],
Fig. 6 Decreased GSK3β immunoreactivities in LBD parietal cortex. a Representative immunoblots and b bar graphs of immunoreactivities
(mean ± SEM in arbitrary units) of total and phosphorylated GSK3β (pTyr216 and pSer9), as well as immunoreactivities of phosphorylated
GSK3β normalized to total GSK3β, with GAPDH used as loading control. Available N for control (C) = 19; PDD (P) = 19 and DLB (D) = 20.
*p < 0.05; **p < 0.01; ***p < 0.001, significant difference for multiple pair-wise comparisons (one-way ANOVA with Bonferroni post-hoc tests)
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LBD, similar with previous finding [58] (Additional file 6:
Figure S6). However, this insoluble pSer129 α-synuclein
also did not correlate with pThr514 CRMP2 level, suggest-
ing this pCRMP2 dysregulation may be directly associated
with Aβ, rather than indirectly via pSer129 α-synuclein
effects of Aβ deposition [58]. However, the observed dif-
ferences in pSer129 α-synuclein in DLB versus PDD are
interesting, and their potential pathogenic and therapeutic
implications should be further investigated.
It would also be of interest to investigate the specificity
of increased CRMP2 phosphorylation at the pThr514
epitope, although this may, again, be due partly to the
need for higher N’s, as pCRMP2 at pSer522 and pThr509
showed trends toward increases (Fig. 1b). Furthermore,
the mechanisms underlying Aβ’s effects on increased
phosphorylation at the Thr514 (and possibly other) site
are currently unclear, as the protein kinases known to
phosphorylate CRMP2 showed alterations which suggest
lower, rather than higher, enzymatic activities. For
example, while CDK5 levels were unaltered, there was a
significant decrease of its activator, p25 in DLB (Fig. 5b).
On the other hand, GSK3β immunoreactivities were lost
in both PDD and DLB, and while phosphorylated GSK3β
(both activating pTyr216 and inactivating pSer9) epitopes
were reduced, they seemed to reflect loss of GSK3β pro-
teins rather than any change in activation status (Fig. 6b).
It is worth noting that GSK3β loss has been reported in
AD and Huntington’s disease [59, 60], and this study adds
both the PDD and DLB subtypes of LBD to the list.
Additionally, p25/p35 have also been reported to be de-
creased in AD [61, 62], although these findings are not
unanimous, as unchanged p35 (together with undetectable
p25) has also been reported [63]. In contrast to the
current findings in LBD, reductions of GSK3β correlated
with decreased pCRMP2 in Huntington’s disease [60].
Because PP2A levels were also unchanged in LBD
(Additional file 6: Fig. 6b), the increased pCRMP2 in LBD
does not seem to be associated with CDK5, GSK3β or
PP2A changes, but may reflect the activities of other, as
yet uncharacterized, kinases or phosphatases. Therefore,
whether the observed reductions of GSK3β and p25 are
adaptive plasticity processes in response to increased
pCRMP2, or are related to other disease process like neur-
onal apoptosis [64], requires further study.
In conclusion, this study demonstrates an increase of
CRMP2 phosphorylation in the DLB parietal cortex spe-
cifically at Thr514, which may be related to fibrillogenic
Aβ load as well as to deficits in axonal growth and syn-
aptic integrity. CRMP2 phosphorylation therefore rep-
resents a mechanism of axonal pathology in DLB with
concomitant Alzheimer pathology, which has implica-
tions in the potential utility of Aβ- or CRMP2-targeting
therapies in this subtype of LBD. However, further stud-
ies are needed to (1) validate the observed pCRMP2
changes in other brain regions in a larger cohort; (2)
elucidate the mechanisms linking Aβ to pCRMP2 in
LBD; and (3) investigate potential associations between
CRMP2 function and other pathological features, in-
cluding various different α-synuclein species.
Methods
Patients and brain tissues
All subjects for this study were selected based on clini-
copathological consensus diagnoses, including the “one-
year rule” [20] and the Movement Disorders Society cri-
teria [65] to distinguish between PDD and DLB, the two
major subtypes of LBD. At death, informed consent was
sought from next-of-kin before removal of brains, and
tissues were collected via the Thomas Willis Oxford
Brain Collections, the London Neurodegenerative Dis-
eases Brain Bank, Newcastle University and University
Hospital Stavanger, the UK sites being part of the Brains
for Dementia Research network. For this study, tissues
from inferior parietal lobe (Brodmann area, BA40) were
collected from 19 aged controls, 19 PDD and 20 DLB
subjects, all of whom had been neuropathologically
assessed by standardized grading instruments, including
Braak staging [66] and the Newcastle/McKeith criteria
for Lewy body disease [20] (see also Howlett et al. [23]).
Not all clinical or neurochemical variables were available
for all samples, and respective N values are listed in the
table and figure legends.
Tissue processing and brain homogenate preparation
All reagent grade chemicals were purchased from
Sigma-Aldrich (USA) unless otherwise stated. Blocks of
frozen brain tissues (around 1 cm3) were thawed on ice
and dissected free of meninges and white matter with
disposable surgical scalpels. After dissection, samples
were homogenized (50 mg tissue wet weight/mL) with
an Ultra-Turrax homogenizer (IKA, Germany, maximum
setting, 10 s) in ice-cold homogenizing buffer (50 mM
Tris-HCl, 120 mM NaCl, 5 mM KCl, 2 μg/mL pepstatin
A, with Complete Mini™ protease inhibitor and Phos-
STOP™ phosphatase inhibitor tablets from Roche Diag-
nostics, USA added at recommended dilutions), then
aliquoted and stored at −75 °C until use. To obtain
insoluble PHF fractions and soluble cytosolic fractions,
dissected brain pieces were dispersed in a glass tissue
grinder at 50 mg tissue wet weight/mL in ice-cold mild
extraction buffer (250 mM sucrose, 20 mM HEPES
pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, with Complete Mini™ protease
inhibitor and PhosSTOP™ phosphatase inhibitor tablets
from Roche Diagnostics, USA added at recommended
dilutions). Dispersed lysates were passed through a 26G
needle 10 times using 1 mL syringes. Lysates were first
centrifuged at 800 × g for 5 min at 4 °C, then at 10,000 × g
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for 10 min at 4 °C, with the resulting supernatant desig-
nated as the cytosolic soluble fraction (after further
centrifugation at 100,000 × g for 1 h at 4 °C) and stored
at −75 °C until use. Pellets resulting from the 800 × g
centrifugation step (see above) were resuspended in 1 %
sarkosyl Tris-buffer, centrifuged (160,000 × g, 50 min
4 °C) with further suspension in 5 M guanidine buffer
for 3 h at 25 °C, then centrifuged again (100,000 × g,
30 min 4 °C) before the final supernatant was desig-
nated as the insoluble sarkosyl PHD fraction [55] and
precipitated using ethanol before immunoblotting. Protein
concentrations were measured using Coomassie Plus™
Assay kits (Thermo Scientific, USA). For immunoblotting,
total or fractionated lysates were mixed 1:1 with Laemmli
Sample Buffer (Bio-Rad, USA) and heated to 95 °C for
5mins. For ELISA assays, homogenates were processed in
ice-cold 5 M guanidine HCl/50 mM Tris–HCl, pH 8.0 as
previously described [54].
Immunoblotting
Samples were loaded on a 10 or 12 % SDS-polyacrylamide
gel and transferred to nitrocellulose membrane using the
iBlot® dry-transfer system (Invitrogen, USA). Membranes
were blocked with 5 % bovine serum albumin (BSA) in
20 mM Tris-buffered saline, pH 7.6 with 0.1 % Tween® 20
(TBST) at 25 °C for 1 h, then incubated with primary anti-
bodies overnight at 4 °C degree in 5 % BSA in TBST at
specified dilutions (see Table 2). At the end of primary
antibody incubation, membranes were washed with TBST
for 4 × 10 min and incubated with the appropriate horse-
radish peroxidase (HRP)-conjugated secondary antibodies
(1: 5,000 dilution, Jackson ImmunoResearch, USA) for 1 h
at 25 °C. Immunoreactivities of antibodies listed in Table 2,
including GAPDH used as loading control, were visualized
with Luminata™ Forte or Crescendo Western HRP sub-
strate (Merck Millipore, Germany) and quantified with
the Alliance 4.7 image analyser (UVItec, UK).
ELISA assays
Aβ40 and Aβ42 concentrations were assessed in duplicates
in aliquots of cytosolic soluble fractions using ELISA kits
(KHB3482 and KHB3442, ThermoFisher Scientific, USA)
according to manufacturer’s instructions. Ratios of Aβ42
to Aβ40 were calculated by dividing values of Aβ42 by
Aβ40. Similarly, pSer396 tau and total tau were assayed
using ELISA kits (KHB7031 and KHB0041, ThermoFisher
Scientific, USA), and ratios of pSer396 tau to total tau
were calculated.
Data analysis
Data was analyzed using SPSS 20.0 (IBM, USA) or Prism
6.0 (GraphPad, USA) software. Comparisons between
groups were assessed with parametric (one way analyses
of variance, ANOVA with Bonferroni post-hoc correc-
tions) or non-parametric (Kruskal-Wallis H tests with
Dunn’s post-hoc corrections) based on normality of the
data, as assessed by Kolmogorov-Smirnov tests. Due to
the ordinal nature of some of the variables, all correla-
tions were based on non-parametric Spearman rank
coefficients. A p-value < 0.05 is considered statistically
significant. As the study is exploratory in nature, no
adjustment for multiple correlations were made.
Table 2 Primary antibodies used for immunoblotting in this study
Antibody (catalogue no.) Species Dilution Company
β-Actin (#2228) mouse mAb 1:5000 Sigma
CDK5 (#2506) rabbit pAb 1:1000 CST
CRMP2, clone C4G (#11096) mouse mAb 1:1000 IBL
CRMP2, pSer522 (#CP2191) rabbit pAb 1:1000 ECM
CRMP2, pThr514 (#9397) rabbit pAb 1:1000 CST
CRMP2, phosphorylated clone 3 F4 (#29060) mouse mAb 1:200 IBL
GAPDH (#G8795) mouse mAb 1:10000 Sigma
GSK3β, clone 3D10 (#9832) mouse mAb 1:500 CST
GSK3β, pSer9 (#5558) rabbit mAb 1:2000 CST
GSK3β, pTyr216 (#ab75745) rabbit pAb 1:2000 Abcam
p35 (#sc-820)a rabbit pAb 1:200 SC
PP2A, C subunit (#2038) rabbit pAb 1:1000 CST
Synaptophysin (#MAB368) mouse mAb 1:2500 MM
α-Synuclein (#sc-7011-R) rabbit pAb 1:500 SC
β-III-Tubulin, clone TU-20 (#ab7751) mouse mAb 1:1000 Abcam
mAB monoclonal antibodies, pAB polyclonal antibodies. Company abbreviations: Abcam Abcam plc (UK), CST Cell Signaling Technology (USA), ECM ECM Biosciences
(USA), IBL IBL-International (Germany), MM Merck-Millipore (Germany), SC Santa Cruz Biotechnology (USA), Sigma Sigma-Aldrich (USA)
aAlso recognizes p25
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Additional files
Additional file 1: Figure S1. CRMP2 is concentrated in cytosol-
enriched fractions of postmortem human neocortex. Representative
CRMP2 immunoblots of total and cytosol-enriched (“Cytosolic”) fractions
of postmortem human neocortex (5 μg protein loaded per lane). β-actin
was used as a control to show concentration of soluble cytoskeletal
proteins, including CRMP2, in the cytosol-enriched fractions using the
fractionation procedure described in Methods. (PDF 116 kb)
Additional file 2: Figure S2. pThr514 CRMP2 is increased in total
homogenate fractions of DLB. a Representative immunoblots (with
molecular weight indicators in kDa to the left) and b bar graphs of
immunoreactivities of total CRMP2 and pThr514 CRMP2 normalized to
total CRMP2 (mean ± SEM in arbitrary units) in total brain homogenate
fractions, with GAPDH used as loading control. Available N for control
(C) = 19; PDD (P) = 19 and DLB (D) = 20. **p < 0.01, significant difference
for multiple pair-wise comparisons (one-way ANOVA with Bonferroni
post-hoc tests). (PDF 145 kb)
Additional file 3: Figure S3. No correlation of pSer522, pThr509 and
3 F4 CRMP2 immunoreactivities with Aβ42 : Aβ40 in LBD parietal cortex.
Scatter plots of soluble Aβ42 to Aβ40 ratio and pCRMP2 phosphorylation
at a Ser522, b Thr509 and c 3 F4 within the combined LBD (DLB + PDD),
DLB and PDD groups. Correlations were assessed by Spearman
correlation, with insets indicating rho and p values. No significant
correlation was observed. (PDF 115 kb)
Additional file 4: Figure S4. No correlation between pThr514 CRMP2
and pSer396 tau in LBD parietal cortex. a Bar graph of mean (± SEM)
pSer396 tau to total tau ratios. Scatter plots of pThr514 CRMP2 with
pSer396 tau : total tau in total homogenate fractions of b LBD (DLB +
PDD), c DLB and d PDD parietal cortex, with insets indicating rho and
p values. Available N for control = 19; PDD = 19 and DLB = 20. No
significant differences (p > 0.05) were found for multiple pair-wise
comparisons of pSer396 : total tau between groups (Kruskal-Wallis H
tests), or for pThr514 CRMP2 correlations with pSer396 tau : total tau
ratios (Spearman). (PDF 106 kb)
Additional file 5: Figure S5. No correlation between pThr514 CRMP2
and α-synuclein immunoreactivity in LBD parietal cortex. a Bar graph
of α-synuclein immunoreactivity (mean ± SEM in arbitrary units) with
representative immunoblots, with GAPDH as loading control. Scatter
plots of pThr514 CRMP2 with α-synuclein immunoreactivity in total
homogenate fractions of b LBD (DLB + PDD), c DLB and d PDD
parietal cortex, with insets indicating rho and p values. Available N
for control (C) = 19; PDD (P) = 19 and DLB (D) = 20. No significant
differences (p > 0.05) were found for multiple pair-wise comparisons
of α-synuclein between groups (one-way ANOVA with Bonferroni’s
post-hoc tests), or for pThr514 CRMP2 correlations with α-synuclein
(Spearman). (PDF 195 kb)
Additional file 6: Figure S6. No correlation between pThr514 CRMP2
and insoluble pSer129 α-synuclein immunoreactivity in LBD parietal
cortex. a Bar graphs of pSer129 α-synuclein normalized to α-synuclein
immunoreactivities in the insoluble fraction (mean ± SEM in arbitrary
units) with representative immunoblots. Scatter plots of pThr514
CRMP2 with pSer129 α-synuclein immunoreactivity of b LBD (DLB +
PDD), c DLB and d PDD parietal cortex, with insets indicating rho
and p values. Available N for control (C) = 19; PDD (P) = 19 and DLB
(D) = 19. One DLB sample was excluded as an outlier due to pSer129
α-synuclein value > 8, the inclusion of which did not alter the significance
of the results (data not shown). *p < 0.05, **p < 0.01, significant differences
for multiple pair-wise comparisons (Kruskal-Wallis H with Dunn’s post-hoc
tests). No significant differences (p > 0.05) were found for pThr514 CRMP2
correlations with pSer129 α-synuclein (Spearman). (PDF 86 kb)
Additional file 7: Figure S7. Unchanged PP2A C-subunit immunoreactivity
in DLB parietal cortex. a Representative immunoblots and b bar graphs
of PP2A C-subunit immunoreactivity (mean ± SEM in arbitrary units),
with GAPDH as loading control. Available N for control (C) = 19; PDD
(P) = 19 and DLB (D) = 20. No significant differences (p > 0.05) were
found for multiple pair-wise comparisons of PP2A C-subunit between
groups (one-way ANOVA with Bonferroni’s post-doc tests). (PDF 133 kb)
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